RATS AND BRIGHT LIGHTS - CTM
By Phillip Day
CTM Chief Executive
One of the most rewarding parts of my job is to see the valuable work of the doctors and biochemists we report vindicated. The poignancy of these brave men and women no longer being around to appreciate the exemplary contribution they made to society's health and longevity only serves to spur us on the mission with more dedication than before. Nutrition is beginning to become a mainstream hot item in cancer science today and about time too.
The following reports will be of great interest to all who have been following the fortunes of our Cancer: Why We're Still Dying to Know the Truth project. In this book we report the work of Professor John Beard, an Edinburgh embryologist who, at the turn of the 20th century, reported that cancer was a healing process that had not terminated, and that this was primarily due to a deficiency of digestive (pancreatic) enzymes, which are used by the body to chew off the protein coating of healing (trophoblast) cells to allow their destruction by the immune system. In the event that trophoblast is not destroyed upon completion of the healing task, the ongoing proliferation of these healing cells will produce tumour mass at the site of original damage. Beard of course had identified the primary role of toxins and carcinogens in being responsible for damaging the body in the first place, triggering a trophoblastic healing reaction.
Beard's work was picked up decades later by dentist William Kelley and Nevada biochemist Ernst T Krebs Jr, who independently, as well as with a limited collaboration, explored the possibility of developing a nutritional protocol for all forms of cancer, which would herald the end of this pernicious disease in our societies. Kelley was an enthusiastic proponent of Vitamin B17 (Laetrile), which Krebs developed from the seeds of apricot kernels, after showing clinically this substance's ability selectively to destroy cancer cells, when used in conjunction with pancreatic enzymes, emulsified Vitamin A and a change in diet. Krebs' studies on nitrilosides amply demonstrated why a number of cultures who ate these B17-rich foods did not contract cancer. Kelley was later instrumental in persuading his friend, actor Steve McQueen to undergo the Metabolic Therapy treatment for his cancer in Mexico. McQueen later died, not of cancer as reported, but of surgical complications to remove a benign tumour in his abdomen.
Dr Harold Manner, in his masterful book The Death of Cancer, replicates the Beard and Krebs research and improves the results with changes of diet to alkalise the body by eliminating acid ash foods from the cancer patient's diet. Interestingly, Kelley, Krebs, Manner and later Kanematsu Sugiura, a renowned 60-year cancer research veteran working at Memorial Sloan-Kettering, received constant harassment and defamation at the hands of their own medical establishment over their assertions that the future of cancer treatments lay in nutrition. The truth was stark: the science to terminate cancer or prevent it completely had been known for a number of years yet had been deliberately suppressed by the American Medical Association, National Cancer Institute and American Cancer Society because of vested interests in the chemotherapy/radiotherapy industry. One medical peer who was a passionate enemy of Laetrile and associated nutritional/enzyme research was one Dr Robert Good, erstwhile president of Memorial Sloan-Kettering, one of America's leading cancer research establishments.
Dr Robert Good effectively killed any further research into nutritional hydrocyanics with B17 to combat cancer, when he deliberately lied at a press conference to denigrate Sugiura's research, which dramatically vindicated the B17 protocol. Good announced: "After careful and exhaustive testing, Laetrile was found to possess neither preventative, nor tumor-regressant, nor anti-metastatic, nor curative anti-cancer activity." Dr Ralph Moss, Assistant Director of Public Relations at MSK, later exposed Good's compliance and cover-up and was fired from his position at the Centre.
And now where do we find Dr Good? Working with Nicholas Gonzalez on pancreatic enzyme and nutritional cures for cancer and claiming glory! From co-opting parts of Max Gerson's detoxification therapies and procedures, through to dietary amendments and using 'a range of supplements' for his patients, Good has made good the final word in medical hypocrisy. On Good's conscience lie the deaths of hundreds of thousands of his fellow Americans and those of countless other cancer patients worldwide, many of whom doubtless could have been saved had Good done the proper thing and reported the medical truth about cancer and nutrition when he had the chance.
Those given positions of extreme power over others have the chance to be great and dispense humanity and knowledge that can heal. Good's meteoric moonshot to the top however will go down in history as a grubby, vainglorious effort to glad-hand and toady his drug peers. In so doing, he has utterly fail the populations who trusted in him and others to do their jobs.
So it is with some poignancy that we can read the following report, which has been fifty to a hundred years in the making, which can now, for the countless brave and suffering cancer souls worldwide, bring a heap of comfort and hope that they can once again think about life and a hope for the future. Now is the time for all of us to get busy and spread the word.
Cancer: Why We're Still Dying to Know the Truth
By Phillip Day
To purchase or review, please visit our online bookstore.
* * * * *
NUTRITION AND CANCER
"THE GONZALEZ STUDY"
Robert W. Maver, FSA, MAAA
(Former) Vice President and Director of Research
Mutual Benefit Life
Kansas City, Missouri
Dr. Nicholas James Gonzalez, who practices in New York City, is using an innovative nutritional protocol to successfully treat far advanced cancer patients. As a classically trained immunologist, he approached this innovative therapy with a great deal of scepticism, but became convinced of its value during an exhaustive five-year research project.
In July of 1981, during the summer preceding his third year at Cornell University Medical College, Dr. Gonzalez embarked upon an informal evaluation of a nutritional approach to cancer. A friend had asked him to look into a dentist named Kelley in Texas who had reportedly cured a patient of terminal cancer [the same Kelley who was the friend and medical mentor for Steve McQueen - Ed.]. What started as a way to spend a summer vacation eventually developed into a five-year research project under the direction of former President of Sloan Kettering Institute, Dr. Robert Good. On his trip to Texas, Gonzalez was astonished to find case after case of appropriately diagnosed, advanced metastatic cancer patients who were healthy and active five, ten, and 15 years after diagnosis. Kelley had made available all of his records, well over 10,000 patients, and encouraged Gonzalez to contact any and all of them.
Gonzalez returned to New York to ask for advice from Dr. Good whom he had befriended when Good was president of Sloan Kettering and Gonzalez was a first-year medical student. Good eventually served as faculty advisor as the study evolved and expanded to an independent research project during Gonzalez' senior year. Though subsequently moving to the University of Oklahoma, Good continued under special arrangement as sponsor and guide. When Good became Chief of Paediatrics at All Children's Hospital at the University of South Florida, Gonzalez joined him to complete the project. Many of the patients followed under this study were examined by both Gonzalez and Good.
Dr. Good had suggested that as an initial goal, fifty terminal cancer patients be identified who had done well on Kelley's nutritional protocol. The patients were to have been diagnosed by appropriate specialists so that there could be no doubt about the diagnosis of cancer.
An initial review of all records between 1970 and 1982 yielded 1306 patients. Contacting these patients by mail produced over 1,000 potential candidates for the study. At this point, lengthy phone interviews were begun essentially starting at the top of the list and concluding once enough patients (455) had been obtained to ensure that at least 50 would meet Dr. Good's strict inclusion criteria.
Eventually the group of 455 patients was reduced to 160 that fit Dr. Good's inclusion criteria. For each of these cases complete medical records were obtained. Follow-up was extensive, including examination of patients, interviews with family and physicians, etc. From these 160 cases, 50 representative cases were chosen and presented in a 300-page manuscript detailing the study. Another 200+ pages, copies of medical records, were included in this as yet unpublished document.
The 50 patients represented 25 different types of cancer. There were 28 males and 22 females, ages 21 to 77 at the start of therapy and 33-83 as of the date of the study.
Patients were included from 24 states and occupation varied widely. Twenty-five of these patients were diagnosed at two or more medical centres. Twenty-three were diagnosed at major institutions, such as Mayo Clinic, Memorial Sloan-Kettering, M.D. Anderson, etc. Forty-eight cases provide biopsy confirmation of cancer. The other two, upon exploratory surgery, were found to have large, inoperable tumors where the attending surgeon thought the diagnosis obvious and did not want to risk biopsy. Median survival of this group of 50 patients, all of whom had terminal or extremely poor prognosis, was 10 years as of the date of study.
As extraordinary as these results were, Dr. Good thought a further step was required. He wanted a numerator/denominator study. Dr. Gonzalez was to pick one type of cancer, identify every patient seeing Kelley with this diagnosis, and follow up on all patients to establish a response rate.
Gonzalez chose pancreatic cancer, since the 5-year survival rate in orthodox medicine is virtually 0%. All patients consulting Kelley between 1974 and 1982 were reviewed to produce 22 who had been diagnosed with pancreatic cancer.
The 22 broke down into three groups. Ten patients consulted Kelley only once and never went on the protocol. All had died. Seven patients followed the protocol only partially and sporadically, as determined by interviews with family members, physicians, and records obtained from the manufacturer/distributor of the special nutritional supplements. These patients had all died. Five patients followed the protocol completely and achieved long-term remission, although one had died (of Alzheimer's) after 11.5 years survival.
The median survival of the three groups was as follows:
1. Never followed (10) = 67 days
2. Followed partially (7) = 233 days
3. Followed completely (5) = 9 years
At this point, Dr. Good and Dr. Gonzalez realized that, even though Kelley's results were extraordinary, in fact unparalleled in medicine, they were of little use in the treatment of cancer unless they could be independently reproduced. This is the stage of the research at present. For the last 3 years, Dr. Gonzalez has been using Kelley's protocol with a few modifications of his own in the treatment of terminal cancer.
The Research Division has been evaluating Dr. Gonzalez' results over the last four months, including numerous site visits. We have interviewed patients at length by phone, met with a number of patients and reviewed case histories of some 40 terminal cancer patients. The results are indeed extraordinary.
We have seen excellent outcomes with a pancreatic cancer case (metastatic to the liver) diagnosed at Mayo Clinic. We have seen return to work for over two years in a case of metastatic melanoma previously operated on twice (unsuccessfully) at Memorial Sloan-Kettering. We have seen long-term survival in terminal lung cancers. We also have two MBL [Mutual Benefit Life] insureds under Dr. Gonzalez' care, one of whom has come back from terminal ovarian cancer (two years ago) to the point where she is preparing to return to work (this is an LTD claim). The other refused a bone marrow transplant after experiencing recurrence of Hodgkin's disease following three different regimens of chemotherapy and radiation that produced short-term remissions. She has been on Dr. Gonzalez' protocol for 15 months.
One of the attractive points of this therapy is the cost. Total cost of the program runs about $5,000 to $6,000 per year. Supplements constitute 70% to 80% of the cost. There is generally no hospitaliztion involved. This is perhaps 10% of the cost we would expect to pay for a terminal cancer patient.
At the conclusion of his manuscript, Dr. Gonzalez stated that his hope was to have this particular nutritional therapy evaluated further under controlled clinical conditions in an academic setting.
Dr. Gonzalez' Protocol, briefly described, consists of six basic components;
1. Appropriate diet - there are 10 basic diets with 94 variations ranging from strict vegetarian to red meat depending on the cancer and the patient.
2. Intensive nutritional support - Depending on each patient's deficiencies, vitamins, minerals, trace elements, electrolytes, and amino acids are prescribed.
3. Protomorphogen support - these are concentrates, in pill form, of raw beef organs and glands.
4. Digestive aids - e.g., pepsin, hydrochloric acid, etc..
5. Pancreatic enzyme therapy - proteolytic pancreatic enzymes are taken orally to attack and liquify tumours.
6. Detoxification - among the many regimens used is the coffee enema. The purpose is to help the body eliminate the unnatural abundance of toxins and waste products as tumors break down in the body.
Nicholas J. Gonzalez, M.D., P.C.
Linda L. Isaacs, M.D.
36A East 36th Street
New York, N.Y. 10016
GOVERNMENT FUNDS TEST OF THE
GONZALEZ NUTRITIONAL CANCER THERAPY
by Peter Barry Chowka
August 15, 1999
Two related developments that occurred without much fanfare in the summer of 1999 may have major ramifications for the future of complementary, alternative medicine -- in particular the field of alternative cancer therapies. In June 1999, the journal Nutrition and Cancer published a study by New York City clinicians Nicholas J. Gonzalez, MD (primary author) and Linda Lee Isaacs, MD reporting impressive survival rates for eleven patients with pancreatic cancer treated with Gonzalez' protocol of diet, nutritional supplements, enzymes, and coffee enemas. Around the same time, it was announced that the National Cancer Institute had awarded an unprecedented $1.4 million grant for a prospective controlled study of Gonzalez' "enzyme-nutritional treatment" versus conventional chemotherapy. The test will involve 70-90 patients with metastasised pancreatic cancer and is being conducted by the prestigious Columbia-Presbyterian Medical Centre, part of Columbia University's College of Physicians and Surgeons.
The federal grant is undoubtedly the largest one ever awarded for a test of an unconventional cancer treatment. According to Gonzalez, "It's the first alternative study -- they tried with [Stanislaw] Burzynski [MD, PhD] but it never got off the ground or it fell apart -- that they [the federal government] have really funded in a big way." Gonzalez' approach is highly unconventional; it is also a primary, comprehensive -- and not a single agent or a complementary -- alternative method. Equally unusual is the fact that, unlike earlier clinical trials of alternative cancer treatments (for example, of vitamin C or laetrile), the chief proponents of the treatment (Gonzalez and Isaacs) will actually provide the therapy to the patients in their own clinical setting and closely oversee their care.
After decades of struggle and disappointments, these developments signal the growing clinical and political viability of alternative cancer treatments.
THE NUTRITION AND CANCER STUDY
Pancreatic cancer (pancreatic adenocarcinoma) is one of the most deadly forms of cancer. Patients treated conventionally have only 25 percent one-year and 10 percent two-year survival rates. From January 1993 through April 1996, Gonzalez and Isaacs monitored eleven pancreatic cancer patients treated in their midtown New York City office. The treatment, according to their article in Nutrition and Cancer, consisted of "large doses of orally ingested pancreatic enzymes, nutritional supplements, 'detoxification' procedures [coffee enemas], and an organic diet" -- and did not include any conventional therapies.
"As of 12 January 1999, nine [of the 11 patients] (81%) survived one year, five (45%) survived two years, and at this time, four have survived three years. Two patients are alive and doing well. . .This pilot study suggests that an aggressive nutritional therapy led to significantly increased survival over what would normally be expected for patients with inoperable pancreatic adenocarcinoma."
It was the results of this pilot study, as well as Gonzalez' low-key and effective lobbying over the years, that led the National Cancer Institute to award the $1.4 million for a more comprehensive, prospective test. Among Gonzalez' influential allies is Rep Dan Burton (R-IN), chairman of the House Committee on Government Reform. In recent years, Burton's Committee has held several hearings on alternative therapies, including cancer. According to a June 25, 1999 statement issued by the Committee, "Burton praised the efforts by Gonzalez to find an alternative treatment and cure for pancreatic cancer. As a result of the Committee's investigation, as well as almost two decades of research, the National Cancer Institute, with funding from the National Centre for Complementary and Alternative Medicine, [is] support[ing] a large-scale, randomised, clinical trial comparing the best conventional treatment for pancreatic cancer to the integrated Gonzalez method."
Burton himself commented, "The Government Reform Committee is committed to increasing the amount of Government-funded research into complementary and alternative cancer treatments and in increasing the information disseminated to the public by the National Institutes of Health on these options. Physicians and patients making treatment decisions need a broader array of options from which to choose. With increased research, we can find these options and hopefully, save some lives."
BACKGROUND OF THE GONZALEZ THERAPY
Some of the roots of the comprehensive non-toxic, nutritionally-based treatment advocated by Gonzalez go back to 1906 and the work of Scottish embryologist Dr. John Beard. In an article that year in the British Medical Journal, Beard proposed, according to Gonzalez and Isaacs, that "pancreatic proteolytic enzymes represent the body's main defence against cancer and would be useful as a cancer treatment." Beard's work was never widely applied, until it was picked up and expanded upon by William Donald Kelley, DDS, a Texas dentist who was active in the cancer underground from the late 1960s through the mid-1980s. Kelley, who said the inspiration for developing a nutrition-based treatment for cancer was his own case of pancreatic cancer, added coffee enemas (based on the work of Max Gerson, MD) and a highly individualized diet and nutritional supplementation regimen to the enzyme therapy, and tailored his treatment according to what he said was the patient's own "metabolic type."
In 1981, when he was a student at Cornell Medical College, and subsequently during a postgraduate immunology fellowship with Robert Good, MD, formerly director of Sloan-Kettering Research Institute, Gonzalez began studying the work of Kelley and evaluating the controversial dentist's voluminous case histories. A retrospective, and so far unpublished, review of 1,306 of Kelley's cancer patients in the mid-1980s by Gonzalez, which yielded 50 best cases, found great benefit of the Kelley treatment. In 1987, Gonzalez himself, according to his article, began "applying proteolytic enzyme therapy to patients with poor-prognosis cancer. The treatment also includes dietary modification, nutritional support in the form of supplements, and detoxification routines. . ."
In June 1993, Gonzalez presented a selection of his own treated cases to the NCI in Bethesda, Maryland. Michael J. Friedman, MD, then Associate Director of the Cancer Therapy Evaluation Program at the NCI, suggested to Gonzalez that he pursue a pilot study of his treatment on patients with pancreatic cancer. Gonzalez' mentor, the late Ernst Wynder, MD, helped Gonzalez secure funding for the pilot study from Nestec (Nestlé -- the "world's largest food company"). It is the results of that study that were published in the summer of 1999 and that led to the new NCI grant.
THE PROSPECTIVE STUDY
John A. Chabot, MD, Associate Professor of Clinical Surgery, Chief, Hepatobiliary & Pancreatic Surgery, Vice Chairman, Dept. of Surgery Columbia University College of Physicians and Surgeons, is the Principal Investigator of the prospective trial of Gonzalez' therapy. Columbia is currently recruiting between 70 and 90 newly diagnosed pancreatic cancer patients (Stages II, III or IV) for the study, one half of whom will be given state-of-the-art conventional chemotherapy, with their results to be compared to the nutrition-only patient group that will be treated by Gonzalez and Isaacs. The patients must be between 18-65 and cannot have had radiation or chemotherapy.
Chabot told the Boston Globe (August 9, 1999), ''Frankly, when I first read'' [about the Gonzalez-Isaacs pilot study in Nutrition and Cancer], ''I said, 'That can't possibly work.' Then I read the pilot data. . .[and] said, 'There really might be something there.' I had to come to grips with it myself. I have no idea how or why it might work, but the data are compelling enough that I can't ignore it. It doesn't matter what the underlying theory is about why it works because I think that's something for us to investigate once we demonstrate that it works.''
I asked Gonzalez if he had to make any compromises to get the federal grant for the clinical trial, and his answer confirmed the unusual nature of the test: "Not really. The only thing Columbia suggested -- They understood that I had individualized [the treatment of] every patient. But with pancreatic cancer, how much variation is there? To be honest, there really isn't that much. They're all on the vegetarian side [needing a vegetarian diet], they all have to do a quart [a day] of carrot juice, the supplement doses tend to be about the same. I wrote the first three or four drafts of the protocol; I actually wrote them myself. I went through Columbia, and they rewrote them. We worked on it together. So any questions or any reservations I had, they addressed them. It's not like [previous controversial or inconclusive tests of alternative cancer treatments] at all. They really were working with me. And I'm going to be the treating physician for the [patients] randomised to my program. I'm the one who is going to be treating the patients."
In a letter from Chabot's office to prospective patients, the Gonzalez protocol that must be followed is described: "The diet is not strictly vegetarian, and does allow some limited animal products. Specifically, you would be expected to eat 1-2 eggs daily, yoghurt daily and fish twice weekly. Red meat and poultry, however, are strictly forbidden. Fried foods, white sugar products such as candy, cakes and carbonated beverages, artificial sweeteners, alcoholic beverages and all refined, white flour products are also completely forbidden.
"In terms of supplements, patients will be required to ingest in the range of 140 capsules a day, spread throughout the day. The supplement portion of the therapy includes vitamin, mineral and trace element capsules, which are generally taken with meals. In addition, each patient takes large numbers of specifically formulated pancreatic proteolytic enzymes.
"The third component of the treatment, the detoxification routines, involves procedures such as coffee enemas which Dr. Gonzalez and Isaacs believe help the body efficiently neutralize and excrete metabolic wastes and tumour breakdown products. Coffee enemas must be done twice each day and are a critically important part of the treatment."
Of the conventional protocol that is the other part of the study, Chabot writes, "If you are assigned to the chemotherapy arm, you will receive gemcitabine, a medication given intravenously on a weekly basis. In recent studies, patients receiving gemcitabine have enjoyed a slight prolongation of life and a significant improvement in their quality of life. The drug will be given as an outpatient by a medical oncologist."
For more information,
Nicholas Gonzalez, MD
Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Nutr Cancer 1999;33(2):117-24 Gonzalez NJ, Isaacs LL (abstract)
Evaluation of Intensive Pancreatic Proteolytic Enzyme Therapy with Ancillary Nutritional Support in the treatment of Inoperable Pancreatic Adenocarcinoma (description of prospective study)
People with pancreatic adenocarcinoma interested in participating in the study are asked to contact Michelle Gabay in Dr. Chabot's office at (212) 305-9468
John A. Chabot, MD